口服阿托伐醌单独及与锑联合用药在实验性内脏利什曼病中的活性。
Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.
作者信息
Murray H W, Hariprashad J
机构信息
Department of Medicine, Cornell University Medical College, New York, New York 10021, USA.
出版信息
Antimicrob Agents Chemother. 1996 Mar;40(3):586-7. doi: 10.1128/AAC.40.3.586.
Abstract
BALB/c mice with established visceral infection caused by the intracellular protozoan Leishmania donovani were treated with oral atovaquone for 7 days. Treatment with 100 mg/kg of body weight per day was optimal and halted parasite replication in the liver. In mice treated with atovaquone, the effect of a suboptimal dose of pentavalent antimony was converted from partially leishmanistatic to leishmanicidal. These results demonstrate the in vivo antileishmanial effect of atovaquone and suggest a potential role for this oral agent in visceral leishmaniasis as an adjunct to conventional antimony treatment.
摘要
对已建立由细胞内原生动物杜氏利什曼原虫引起的内脏感染的BALB/c小鼠，口服阿托伐醌治疗7天。每天100 mg/kg体重的治疗剂量最佳，可使肝脏中的寄生虫复制停止。在用阿托伐醌治疗的小鼠中，次优剂量的五价锑的作用从部分抑制利什曼原虫转变为杀利什曼原虫。这些结果证明了阿托伐醌的体内抗利什曼原虫作用，并表明这种口服药物在内脏利什曼病中作为传统锑治疗辅助药物的潜在作用。
相似文献
1
Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.口服阿托伐醌单独及与锑联合用药在实验性内脏利什曼病中的活性。
Antimicrob Agents Chemother. 1996 Mar;40(3):586-7. doi: 10.1128/AAC.40.3.586.
2
Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.内脏利什曼病的脂质体免疫化疗联合疗法
Arzneimittelforschung. 1999 Nov;49(11):954-61.
3
Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis.游离及脂质体包裹的阿托伐醌治疗小鼠利什曼病的疗效评估
Int J Parasitol. 2000 May;30(6):777-83. doi: 10.1016/s0020-7519(00)00053-9.
4
Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.积雪草苷通过诱导肿瘤坏死因子-α产生一氧化氮来治愈对锑敏感和耐药的杜氏利什曼原虫引起的实验内脏利什曼病。
J Antimicrob Chemother. 2012 Apr;67(4):910-20. doi: 10.1093/jac/dkr575. Epub 2012 Jan 18.
5
Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.使用含硬脂胺脂质体的葡萄糖酸锑钠对BALB/c小鼠已建立的慢性杜氏利什曼原虫感染进行联合治疗。
Antimicrob Agents Chemother. 2004 Sep;48(9):3591-3. doi: 10.1128/AAC.48.9.3591-3593.2004.
6
Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.次优剂量的葡萄糖酸锑钠（SAG）-双过氧钒酸盐组合通过扩大抗利什曼原虫T细胞库并提高IFN-γ与IL-10的比例，清除感染了抗锑杜氏利什曼原虫的BALB/c小鼠体内的器官寄生虫。
Exp Parasitol. 2009 Jun;122(2):145-54. doi: 10.1016/j.exppara.2009.02.001.
7
Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.五价锑-甘露聚糖共轭物治疗实验性内脏利什曼病
Am J Trop Med Hyg. 1996 Oct;55(4):444-6. doi: 10.4269/ajtmh.1996.55.444.
8
Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis.基于树突状细胞的免疫疗法联合锑基化疗可治愈已建立的小鼠内脏利什曼病。
J Immunol. 2003 Jun 1;170(11):5625-9. doi: 10.4049/jimmunol.170.11.5625.
9
Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis.游离阿托伐醌和纳米胶囊包裹的阿托伐醌治疗小鼠内脏利什曼病的疗效评估
Ann Trop Med Parasitol. 2003 Apr;97(3):259-68. doi: 10.1179/000349803235001840.
10
Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.白细胞介素10受体阻断——五价锑治疗实验性内脏利什曼病
Acta Trop. 2005 Mar;93(3):295-301. doi: 10.1016/j.actatropica.2004.11.008.
引用本文的文献
1
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.抗利什曼病疫苗设计技术：当前挑战与启示
Curr Drug Discov Technol. 2025;22(2):e240524230315. doi: 10.2174/0115701638291767240513113400.
2
Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions of () -infected hamsters.纹身途径给予低剂量的 3-苯基-劳森或葡甲胺锑可成功降低 () 感染仓鼠皮肤损伤中的寄生虫负荷。
Front Cell Infect Microbiol. 2023 Jan 19;13:1025359. doi: 10.3389/fcimb.2023.1025359. eCollection 2023.
3
The anti-Leishmania potential of bioactive compounds derived from naphthoquinones and their possible applications. A systematic review of animal studies.来源于萘醌类化合物的生物活性化合物的抗利什曼原虫潜力及其可能的应用。动物研究的系统评价。
Parasitol Res. 2022 May;121(5):1247-1280. doi: 10.1007/s00436-022-07455-1. Epub 2022 Feb 22.
4
Meglumine antimoniate combination treatment for relapsing Kala-azar after treatment and secondary prophylaxis failure with liposomal amphotericin B in two HIV-coinfected patients.在两名合并感染HIV的患者中，用葡甲胺锑酸盐联合治疗脂质体两性霉素B治疗及二级预防失败后的复发性黑热病。
BMJ Case Rep. 2019 Dec 16;12(12):e231929. doi: 10.1136/bcr-2019-231929.
5
Atovaquone Impairs Growth of Aspergillus and Fusarium Keratitis Isolates by Modulating Mitochondrial Function and Zinc Homeostasis.阿托伐醌通过调节线粒体功能和锌稳态来抑制曲霉菌和镰刀菌角膜炎分离株的生长。
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1589-1598. doi: 10.1167/iovs.17-22585.
6
Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.DB766-唑类联合的抗利什曼原虫疗效和药代动力学。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01129-17. Print 2018 Jan.
7
Synthesis and in vitro Screening of 29, 30-Dibromo-28-oxoallobetulin against Parasitic Protozoans, Leishmania donovani and Leishmania Major.29,30-二溴-28-氧代别白桦脂醇对寄生原生动物杜氏利什曼原虫和硕大利什曼原虫的合成及体外筛选
Indian J Pharm Sci. 2015 Mar-Apr;77(2):202-7. doi: 10.4103/0250-474x.156596.
8
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.米替福新与其他抗利什曼原虫药物的体外和体内相互作用。
Antimicrob Agents Chemother. 2006 Jan;50(1):73-9. doi: 10.1128/AAC.50.1.73-79.2006.
9
10
Clinical and experimental advances in treatment of visceral leishmaniasis.内脏利什曼病治疗的临床与实验进展
Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001.
本文引用的文献
1
Practical progress and new drugs for changing patterns of leishmaniasis.改变利什曼病模式的实际进展与新药
Parasitol Today. 1993 Sep;9(9):323-8. doi: 10.1016/0169-4758(93)90231-4.
2
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.苏丹的流行性内脏利什曼病：氨基胍啶加葡萄糖酸锑钠与单用葡萄糖酸锑钠的随机试验。
J Infect Dis. 1993 Sep;168(3):715-20. doi: 10.1093/infdis/168.3.715.
3
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.T细胞缺陷宿主中实验性内脏利什曼病的治疗：对两性霉素B和喷他脒的反应
Antimicrob Agents Chemother. 1993 Jul;37(7):1504-5. doi: 10.1128/AAC.37.7.1504.
4
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.羟萘醌阿托伐醌单独或与乙胺嘧啶、磺胺嘧啶、克拉霉素或米诺环素联合使用对刚地弓形虫的体外和体内活性。
Antimicrob Agents Chemother. 1993 Nov;37(11):2371-8. doi: 10.1128/AAC.37.11.2371.
5
Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.在印度使用锑剂加γ-干扰素成功治疗难治性内脏利什曼病。
J Infect Dis. 1994 Sep;170(3):659-62. doi: 10.1093/infdis/170.3.659.
6
Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.针对小鼠肺孢子虫病和弓形虫病联合预防的实验评估
J Infect Dis. 1994 Sep;170(3):653-8. doi: 10.1093/infdis/170.3.653.
7
Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.两性霉素与葡萄糖酸锑钠在印度黑热病一线治疗中的对比
Lancet. 1994 Dec 10;344(8937):1599-600. doi: 10.1016/s0140-6736(94)90406-5.
8
Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.口服8-氨基喹啉（WR6026）治疗内脏利什曼病的2期疗效试验。
Clin Infect Dis. 1994 Dec;19(6):1034-9. doi: 10.1093/clinids/19.6.1034.
9
Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis.用于全身性细胞内感染的免疫化疗：在内脏利什曼病中使用γ干扰素加速反应。
J Infect Dis. 1995 Apr;171(4):992-6. doi: 10.1093/infdis/171.4.992.
10
Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.印度葡萄糖酸锑钠治疗黑热病方案的合理化：一项随机研究。
Br Med J (Clin Res Ed). 1988 Jun 4;296(6636):1557-61. doi: 10.1136/bmj.296.6636.1557.
Zotero 插件